Verici DX Logo
June 4-8, 2022. Boston, MA

Join us for the american transplant conference

» Register Today

Verici Dx kidney transplant tests use next-generation sequencing to define a personalized, precise risk-profile of each patient over the course of their transplant journey, as well as detecting injury in advance of current clinical and pathological tests.

About Verici Dx

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterized data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Technology Underlying the Verici Dx Tests

Latest News

January 8, 2024

Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of January 1, 2024

Verici Dx announces announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule (“CLFS”) payment rate
» Read More
1 2 3 72